Compare JJSF & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | AGIO |
|---|---|---|
| Founded | 1971 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2013 |
| Metric | JJSF | AGIO |
|---|---|---|
| Price | $82.73 | $27.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $138.33 | $36.25 |
| AVG Volume (30 Days) | 222.7K | ★ 939.7K |
| Earning Date | 02-03-2026 | 02-12-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.36 | N/A |
| Revenue | ★ $1,583,233,000.00 | $44,791,000.00 |
| Revenue This Year | $4.22 | $27.83 |
| Revenue Next Year | $2.24 | $133.46 |
| P/E Ratio | $28.33 | ★ N/A |
| Revenue Growth | 0.54 | ★ 36.26 |
| 52 Week Low | $80.67 | $22.24 |
| 52 Week High | $144.37 | $46.00 |
| Indicator | JJSF | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 27.27 | 48.17 |
| Support Level | $93.11 | $26.53 |
| Resistance Level | $97.28 | $29.93 |
| Average True Range (ATR) | 3.38 | 1.21 |
| MACD | -0.98 | 0.07 |
| Stochastic Oscillator | 9.77 | 42.26 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.